Track market-moving stories before they get noisy

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at LifeStance Health Group (LFST - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. LifeStance Health Group currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for LFST that show why this outpatient mental health services provider shows promise as a solid momentum pick.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For LFST, shares are up 9.63% over the past week while the Zacks Medical - Outpatient and Home Healthcare industry is up 5.14% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 42.3% compares favorably with the industry's 12% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of LifeStance Health Group have risen 67.43%, and are up 130.44% in the last year. In comparison, the S&P 500 has only moved 13.69% and 21.71%, respectively.

Investors should also pay attention to LFST's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. LFST is currently averaging 4,002,606 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with LFST.

Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost LFST's consensus estimate, increasing from $0.11 to $0.12 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.

Bottom LineGiven these factors, it shouldn't be surprising that LFST is a #1 (Strong Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep LifeStance Health Group on your short list.

Analysis of 180,000 Patients Validates Measurement-Informed Care for Anxiety and Depression

, /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental health care, published new clinical outcomes data demonstrating that LifeStance patients treated for anxiety and depression broadly experienced clinically significant improvements in their symptoms.

The analysis included nearly 180,000 patients who initiated care between September 2024 and December 2025 across the 33 states LifeStance serves. Key findings include:

Anxiety improvement: 79% of LifeStance patients showed clinically significant improvements in symptoms of anxiety* Depression improvement: 73% of LifeStance patients showed clinically significant improvements in symptoms of depression* Results were consistent across all U.S. geographic regions *Among 140,000 individuals with at least moderate anxiety and 150,000 individuals with at least moderate depression.

Patients were evaluated using two widely used mental health screening tools: the GAD-7 for anxiety and the PHQ-9 for depression. Through LifeStance's measurement‑informed care model, patients complete GAD‑7 and PHQ‑9 assessments at regular intervals, allowing clinicians to track progress over time and adjust care as needed.

LifeStance is committed to clinical excellence and delivering high-quality care. Its model is designed to support improved patient outcomes, including in-person and telehealth options to expand access and support patient engagement; integrated therapy and medication management for more comprehensive and personalized care; and measurement-informed practices that allow clinicians to track and adjust treatment over time.

"For too long, patients seeking mental health care have not had the same clear way to track progress that exists in other areas of medicine, like a blood pressure reading or an A1C result," said Dr. Stephanie Eken, Chief Medical Officer, LifeStance. "Measurement-informed care is changing that dynamic. Our data shows that when patients receive high-quality mental health care, they get better—and LifeStance is demonstrating that at scale."

The full anxiety and depression treatment outcomes analysis is available at LifeStance.com.

About LifeStance
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 8,000 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers.

Contacts:
Media relations: [email protected]
Investor relations: [email protected]

SOURCE LifeStance Health

Also from this source

Posted by Defense World Staff on Apr 27th, 2026

Chemed (NYSE:CHE – Get Free Report) and LifeStance Health Group (NASDAQ:LFST – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership 95.9% of Chemed shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 6.6% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations This is a summary of current ratings and target prices for Chemed and LifeStance Health Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 2 2 2 0 2.00 LifeStance Health Group 0 2 6 1 2.89 Chemed currently has a consensus target price of $498.00, suggesting a potential upside of 18.38%. LifeStance Health Group has a consensus target price of $9.83, suggesting a potential upside of 39.48%. Given LifeStance Health Group’s stronger consensus rating and higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than Chemed.

Earnings & Valuation This table compares Chemed and LifeStance Health Group”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53 billion 2.43 $265.24 million $18.35 22.92 LifeStance Health Group $1.42 billion 1.92 $9.66 million $0.02 352.50 Chemed has higher revenue and earnings than LifeStance Health Group. Chemed is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk Chemed has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Profitability This table compares Chemed and LifeStance Health Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% LifeStance Health Group 0.68% 0.65% 0.45% Summary Chemed beats LifeStance Health Group on 8 of the 15 factors compared between the two stocks.

About Chemed (Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

About LifeStance Health Group (Get Free Report)

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINELondon Stock Exchange Group plc – Unsponsored ADR (OTCMKTS:LNSTY) Receives Average Recommendation of “Buy” from Analysts

NEXT HEADLINE »Speed Commerce (OTCMKTS:SPDC) versus A2Z Cust2Mate Solutions (NASDAQ:AZ) Head to Head Comparison

Director Robert Bessler reported the sale of 69,899 shares of LifeStance Health Group (LFST 0.81%) in multiple open-market transactions valued at approximately $492,000, according to the SEC Form 4 filing.

Transaction summaryMetricValueShares sold (indirect)69,899Transaction value~$492KPost-transaction shares (direct)57,619Post-transaction shares (indirect)2,702,057Post-transaction value (direct ownership)~$406KTransaction and post-transaction values based on SEC Form 4 weighted average sell price of $7.04 on April 24, 2026.

Key questionsHow does this sale compare to Bessler's historical transaction size and cadence?
This transaction aligns with Bessler's historical average sell-only trade size of approximately 53,600 shares, and follows a recent series of disposals that have meaningfully reduced his available share capacity.What proportion of Bessler's total position was affected, and what remains?
The sale represented 2.47% of his total holdings, leaving him with 57,619 shares directly and 2.7 million shares indirectly.Were any direct holdings impacted by this transaction?
No direct shares were sold; all activity was executed through indirect holdings.Is this transaction likely to alter Bessler's influence or alignment with shareholders?
Given the small percentage of overall holdings sold, and the substantial remaining indirect position, Bessler retains a meaningful economic interest in LifeStance Health Group.Company overviewMetricValueEmployees7,535Revenue (TTM)$1.42 billionNet income (TTM)$9.66 million1-year price change8.60%* 1-year price change calculated using April 24, 2026 as the reference date.

Company snapshotLifeStance Health Group provides outpatient mental health services, including psychiatric evaluations, psychological and neuropsychological testing, and individual, family, and group therapy, both virtually and in-person across 32 states.It operates a hybrid care delivery model combining physical centers and a digital platform, generating revenue through direct patient services.The company serves a broad demographic, including children, adolescents, adults, and geriatrics seeking mental health care.LifeStance Health Group provides outpatient mental health services in the United States, leveraging a blend of in-person and virtual care. The company’s expansive network and technology-enabled platform enable access to behavioral health services for diverse patient populations.

What this transaction means for investorsBoard of Directors member Dr. Robert Bessler’s sale of LifeStance stock on April 23 and 24 is not a cause for concern for investors. He retained over 2.7 million indirectly-held as well as nearly 60,000 directly-held  shares after the transaction, indicating he is maintaining a sizable equity stake in the company.

The sale came at a time when LifeStance stock was soaring. Shares reached a 52-week high of $8.09 in February. The stock is up thanks to strong business performance.

LifeStance ended 2025 with full year revenue of $1.4 billion, representing a 14% year-over-year increase. The company also made a dramatic turnaround in its bottom line, delivering net income of $9.7 million in 2025 compared to a net loss of $57.4 million in 2024.

As a result of its share price jump, LifeStance Health’s forward price-to-sales ratio of two is elevated, making it a good time to sell. The company expects 2026 revenue to come in around $1.6 billion, showing that its business continues to grow. So while the forward sales multiple is up, now may still be an opportunity to buy as well.

Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

2026 Highlights and FY 2026 Outlook

Revenue of $403.5 million increased 21% compared to revenue of $333.0 millionClinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarterFirst quarter visit volumes increased 18% to 2.5 millionNet income of $14.2 million compared to net income of $0.7 millionAdjusted EBITDA of $51.1 million compared to Adjusted EBITDA of $34.6 millionNet cash provided by operations of $33.1 million in the first quarterFree Cash Flow generation of $22.3 million in the first quarterFor full year 2026, raising revenue expectations to $1.640 billion to $1.680 billion, Center Margin expectations to $547 million to $571 million, and Adjusted EBITDA of $200 million to $220 million “We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance. “Our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare. We also took an important step forward in our commitment to clinical excellence by announcing an outcomes study on approximately 180,000 LifeStance patients that showed roughly three quarters reported clinically significant improvement in anxiety and depression.”

          Financial Highlights           Q1 2026  Q1 2025  Y/Y (in millions)         Total revenue $403.5  $333.0   21%Income from operations  22.3   1.6  NM Center Margin  135.9   109.8   24%Net income  14.2   0.7  NM Adjusted EBITDA  51.1   34.6   48%As % of Total revenue:         Income from operations  5.5%  0.5%   Center Margin  33.7%  33.0%   Net income  3.5%  0.2%   Adjusted EBITDA  12.7%  10.4%               NM - not meaningful                        (All results compared to prior-year period, unless otherwise noted)

Revenue grew 21% to $403.5 million. Revenue growth in the first quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.Income from operations was $22.3 million and net income was $14.2 million.Center Margin grew 24% to $135.9 million, or 33.7% of total revenue.Adjusted EBITDA increased 48% to $51.1 million, or 12.7% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the first quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses. Balance Sheet, Cash Flow, and Capital Allocation

For the three months ended March 31, 2026, LifeStance generated $33.1 million cash flow from operations. The Company ended the first quarter with cash of $194.8 million and net long-term debt of $262.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

The Company is raising full year revenue to $1.640 billion to $1.680 billion, Center Margin to $547 million to $571 million, and Adjusted EBITDA to $200 million to $220 million.For the second quarter of 2026, the Company expects total revenue of $405 million to $425 million, Center Margin of $135 million to $147 million, and Adjusted EBITDA of $50 million to $60 million. Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, May 7, 2026 at 8:30 a.m. Eastern Time to discuss the first quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 8795477 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and second quarter guidance and management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by (used in) operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income or income from operations.

Center Margin and Adjusted EBITDA anticipated for the second quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking second quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

Consolidated Financial Information and Reconciliations

 CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except for par value)
   March 31, 2026  December 31, 2025 CURRENT ASSETS      Cash and cash equivalents $194,797  $248,642 Patient accounts receivable, net  122,916   95,710 Prepaid expenses and other current assets  38,198   71,848 Total current assets  355,911   416,200 NONCURRENT ASSETS      Property and equipment, net  161,468   161,583 Right-of-use assets  151,526   149,720 Intangible assets, net  175,141   177,665 Goodwill  1,296,999   1,293,346 Other noncurrent assets  4,837   5,419 Total noncurrent assets  1,789,971   1,787,733 Total assets $2,145,882  $2,203,933 LIABILITIES AND STOCKHOLDERS' EQUITY      CURRENT LIABILITIES      Accounts payable $4,292  $6,122 Accrued payroll expenses  117,306   143,327 Other accrued expenses  52,408   42,187 Operating lease liabilities, current  47,369   45,544 Other current liabilities  18,357   14,782 Total current liabilities  239,732   251,962 NONCURRENT LIABILITIES      Long-term debt, net  262,459   265,927 Operating lease liabilities, noncurrent  148,821   148,553 Deferred tax liability, net  16,408   16,408 Other noncurrent liabilities  1,046   68 Total noncurrent liabilities  428,734   430,956 Total liabilities $668,466  $682,918 COMMITMENTS AND CONTINGENCIES      STOCKHOLDERS’ EQUITY      Preferred stock – par value $0.01 per share; 25,000 shares authorized as of
March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as
of March 31, 2026 and December 31, 2025  —   — Common stock – par value $0.01 per share; 800,000 shares authorized as of
March 31, 2026 and December 31, 2025; 387,813 and 388,318 shares
issued and outstanding as of March 31, 2026 and December 31, 2025,
respectively  3,878   3,883 Additional paid-in capital  2,267,921   2,325,758 Accumulated deficit  (794,383)  (808,626)Total stockholders' equity  1,477,416   1,521,015 Total liabilities and stockholders’ equity $2,145,882  $2,203,933            CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(unaudited)
(In thousands, except per share amounts)
   Three Months Ended March 31,   2026  2025 TOTAL REVENUE $403,476  $332,970 OPERATING EXPENSES      Center costs, excluding depreciation and
amortization shown separately below  267,544   223,179 General and administrative expenses  100,330   94,431 Depreciation and amortization  13,318   13,756 Total operating expenses $381,192  $331,366 INCOME FROM OPERATIONS $22,284  $1,604 OTHER EXPENSE      Loss on remeasurement of contingent consideration  (5)  — Transaction costs  (544)  — Interest expense, net  (1,793)  (3,073)Other expense  (182)  (1)Total other expense $(2,524) $(3,074)INCOME (LOSS) BEFORE INCOME TAXES  19,760   (1,470)INCOME TAX (PROVISION) BENEFIT  (5,517)  2,179 NET INCOME $14,243  $709 EARNINGS PER SHARE      Basic  0.04   0.00 Diluted  0.04   0.00 Weighted-average shares outstanding      Basic  387,264   383,272 Diluted  395,084   390,666        NET INCOME $14,243  $709 OTHER COMPREHENSIVE LOSS      Unrealized losses on cash flow hedge, net of tax  —   (317)COMPREHENSIVE INCOME $14,243  $392            CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
   Three Months Ended March 31,   2026  2025 CASH FLOWS FROM OPERATING ACTIVITIES      Net income $14,243  $709 Adjustments to reconcile net income to net cash provided by
(used in) operating activities:      Depreciation and amortization  13,318   13,756 Non-cash operating lease costs  10,717   10,231 Stock-based compensation  15,201   18,584 Amortization of discount and debt issue costs  251   251 Other, net  129   357 Change in operating assets and liabilities, net of businesses acquired:      Patient accounts receivable, net  (26,953)  (8,568)Prepaid expenses and other current assets  33,779   (4,515)Accounts payable  (1,017)  (77)Accrued payroll expenses  (26,362)  (17,540)Operating lease liabilities  (9,955)  (11,894)Other accrued expenses  9,758   (4,386)Net cash provided by (used in) operating activities $33,109  $(3,092)CASH FLOWS FROM INVESTING ACTIVITIES      Purchases of property and equipment  (10,767)  (7,168)Acquisitions of businesses, net of cash acquired  (3,144)  — Net cash used in investing activities $(13,911) $(7,168)CASH FLOWS FROM FINANCING ACTIVITIES      Payments of long-term debt  —   (1,813)Taxes related to net share settlement of equity awards  (23,936)  (8,162)Repurchases of common stock  (49,107)  — Net cash used in financing activities $(73,043) $(9,975)NET DECREASE IN CASH AND CASH EQUIVALENTS  (53,845)  (20,235)Cash and cash equivalents - beginning of period  248,642   154,571 CASH AND CASH EQUIVALENTS – END OF PERIOD $194,797  $134,336 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      Cash paid for interest, net $77  $4,382 Cash paid for taxes, net of refunds $349  $609 SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND
FINANCING ACTIVITIES      Contingent consideration incurred in acquisitions of businesses $1,008  $— Acquisition of property and equipment included in liabilities $2,489  $2,348            RECONCILIATION OF INCOME FROM OPERATIONS TO CENTER MARGIN
   Three Months Ended March 31,   2026  2025 (in thousands)      Income from operations $22,284  $1,604 Adjusted for:      Depreciation and amortization  13,318   13,756 General and administrative expenses(1)  100,330   94,431 Center Margin $135,932  $109,791            (1) Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.      RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
   Three Months Ended March 31,   2026  2025 (in thousands)      Net income $14,243  $709 Adjusted for:      Interest expense, net  1,793   3,073 Depreciation and amortization  13,318   13,756 Income tax provision (benefit)  5,517   (2,179)Loss on remeasurement of contingent consideration  5   — Stock-based compensation expense  15,201   18,584 Loss on disposal of assets  182   1 Transaction costs(1)  544   — Executive transition costs  —   185 Litigation costs(2)  (197)  205 Strategic initiatives(3)  86   — Real estate optimization and restructuring charges(4)  —   (45)Amortization of cloud-based software implementation costs(5)  418   357 Adjusted EBITDA $51,110  $34,646            (1) Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offering of shares of our common stock by certain selling stockholders completed in the first quarter of 2026. (2) Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three months ended March 31, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three months ended March 31, 2025, a compensation model class action litigation. (3) Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. (4) Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three months ended March 31, 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023. (5) Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has authorized the concurrent purchase from the underwriter of 6,000,000 shares of Common Stock (the “Repurchase”), subject to the completion of the offering. The price per share for the shares to be repurchased by the Company will be the same as the price per share payable by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The Repurchase will be subject to completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering will be made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. 

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $8.15 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has agreed to purchase from the underwriter 6,000,000 shares of Common Stock to be sold by the Selling Stockholders in the offering, at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders (the “Repurchase”). The Repurchase is conditioned upon the completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase. The underwriter will not receive any compensation for the shares of Common Stock being purchased by the Company.

Subject to customary closing conditions, the offering and the Repurchase are expected to settle and close on or about May 12, 2026.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering is being made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the
Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

Shares of LifeStance Health Group (LFST - Free Report) have gained 21.8% over the past four weeks to close the last trading session at $7.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.39 indicates a potential upside of 31%.

The mean estimate comprises nine short-term price targets with a standard deviation of $1.58. While the lowest estimate of $8.00 indicates a 0.9% increase from the current price level, the most optimistic analyst expects the stock to surge 63.9% to reach $13.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

However, an impressive consensus price target is not the only factor that indicates a potential upside in LFST. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why LFST Could Witness a Solid UpsideThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The Zacks Consensus Estimate for the current year has increased 26.9% over the past month, as two estimates have gone higher compared to no negative revision.

Moreover, LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much LFST could gain, the direction of price movement it implies does appear to be a good guide.

LifeStance Health Group (LFST - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this outpatient mental health services provider, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For LifeStance Health Group, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $0.02 per share, which is a change of +300.0% from the year-ago reported number.

Over the last 30 days, two estimates have moved higher for LifeStance Health compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 40%.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.11 per share represents a change of +450.0% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for LifeStance Health. Over the past month, two estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 26.92%.

Favorable Zacks RankThe promising estimate revisions have helped LifeStance Health earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineInvestors have been betting on LifeStance Health because of its solid estimate revisions, as evident from the stock's 21.8% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

A downtrend has been apparent in LifeStance Health Group (LFST - Free Report) lately. While the stock has lost 5.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.

The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this outpatient mental health services provider enhances its prospects of a trend reversal.

What is a Hammer Chart and How to Trade It?This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.

When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.

Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.

Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.

Here's What Makes the Trend Reversal More Likely for LFSTAn upward trend in earnings estimate revisions that LFST has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

Over the last 30 days, the consensus EPS estimate for the current year has increased 42.3%. What it means is that the sell-side analysts covering LFST are majorly in agreement that the company will report better earnings than they predicted earlier.

If this is not enough, you should note that LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Moreover, a Zacks Rank of 1 for LifeStance Health is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.